Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01735630 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Phase 2 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
NCT01735630 is a Phase 2 study that has completed, run by OPKO Health. The registered enrollment target is 350 participants.
The verdict
NCT01735630, a Phase 2 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
Interventions
- DRUG Placebo
- DRUG ELND005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01735630
The ClinicalTrials.gov registry entry for NCT01735630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01735630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01735630 about?
NCT01735630 is a clinical study titled "Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease". The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
What is the current status of trial NCT01735630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2012-11. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01735630?
The interventions under investigation include: Placebo (DRUG), ELND005 (DRUG).
Who is sponsoring clinical trial NCT01735630?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.